chartexchange

Caribou Biosciences to Discontinue CAR-T Programs, Opens Strategic Review

Securities.io | Oct 6, 2026 4:23 PM EDT

Caribou Biosciences announced on October 6, 2026 that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development of its two allogeneic CAR-T cell therapy programs, vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma, while implementing a substantial workforce reduction expected to be mostly complete in the fourth quarter of 2026. The Berkeley, California-based…

Read original article